Pavan Reddy

Dr. Pavan Reddy is a Professor, Director of the Dan L Duncan Comprehensive Cancer Center, and Senior Associate Dean for Cancer Programs at Baylor College of Medicine in Houston, Texas. He holds an MD from Osmania University (India) and completed residencies in Internal Medicine and Hematology/Oncology at the University of Missouri and University of Michigan. His research focuses on immunobiology of graft-versus-host disease (GVHD), cellular/molecular immunology, and translational therapies in hematopoietic cell transplantation (HCT). Key contributions include elucidating GVHD mechanisms, non-coding RNA roles, and clinical trials of novel GVHD prevention strategies. His work is supported by NIH grants and he holds leadership roles in societies like the American Society of Transplantation and Cell Therapy. As Cancer Center Director, he emphasizes transdisciplinary research and community engagement.

Education:

• MD, Osmania University, Hyderabad, India
• Residency in Internal Medicine, University of Missouri
• Fellowship in Hematology/Oncology and Bone Marrow Transplantation, University of Michigan

Professional Leadership:

• President, American Society of Transplantation and Cell Therapy (2020–2021)
• Section Editor, Current Opinion in Hematology (2019–2024)
• Chair, ASH Awards Review Subcommittee (2017–2021)

Research Focus:

Dr. Reddy’s lab investigates GVHD pathogenesis, microbiome-metabolite interactions, and T-cell alloimmunity. They pioneered dietary interventions to modulate gut microbiota and developed therapies targeting mitochondrial pathways in intestinal epithelial cells. His work bridges basic science and clinical trials, with multiple approaches now in national trials.

Key Awards:

• Presidential Lecture, City of Hope Cancer Center (2022)
• NIH-funded grants for over a decade

Grants & Advising:

Recipient of multiple NIH grants; no listed advisees/students. His grants focus on GVHD mechanisms and translational therapies.

Labs/Teams:

Leads a multidisciplinary team at the Dan L Duncan Cancer Center, fostering collaboration between immunologists, oncologists, and engineers to address GVHD and cancer treatment challenges.